175 related articles for article (PubMed ID: 20308314)
21. A combined preclinical therapy of cannabinoids and temozolomide against glioma.
Torres S; Lorente M; Rodríguez-Fornés F; Hernández-Tiedra S; Salazar M; García-Taboada E; Barcia J; Guzmán M; Velasco G
Mol Cancer Ther; 2011 Jan; 10(1):90-103. PubMed ID: 21220494
[TBL] [Abstract][Full Text] [Related]
22. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X
Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123
[TBL] [Abstract][Full Text] [Related]
23. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
Tentori L; Leonetti C; Scarsella M; D'Amati G; Vergati M; Portarena I; Xu W; Kalish V; Zupi G; Zhang J; Graziani G
Clin Cancer Res; 2003 Nov; 9(14):5370-9. PubMed ID: 14614022
[TBL] [Abstract][Full Text] [Related]
24. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA
Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956
[TBL] [Abstract][Full Text] [Related]
25. DMC is not better than TMZ on intracranial anti-glioma effects.
Shi L; Sun G
J Cell Biochem; 2018 Jul; 119(7):6057-6064. PubMed ID: 29575236
[TBL] [Abstract][Full Text] [Related]
26. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
27. Multifaceted resistance of gliomas to temozolomide.
Bocangel DB; Finkelstein S; Schold SC; Bhakat KK; Mitra S; Kokkinakis DM
Clin Cancer Res; 2002 Aug; 8(8):2725-34. PubMed ID: 12171906
[TBL] [Abstract][Full Text] [Related]
28. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
[TBL] [Abstract][Full Text] [Related]
29. miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
Li S; Zeng A; Hu Q; Yan W; Liu Y; You Y
Neuro Oncol; 2017 Jan; 19(1):55-65. PubMed ID: 27471108
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
31. Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination.
Reich TR; Schwarzenbach C; Vilar JB; Unger S; Mühlhäusler F; Nikolova T; Poplawski A; Baymaz HI; Beli P; Christmann M; Tomicic MT
Cell Mol Life Sci; 2021 Jul; 78(14):5587-5604. PubMed ID: 34100981
[TBL] [Abstract][Full Text] [Related]
32. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174
[TBL] [Abstract][Full Text] [Related]
33. Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.
Jaime-Ramirez AC; Dmitrieva N; Yoo JY; Banasavadi-Siddegowda Y; Zhang J; Relation T; Bolyard C; Wojton J; Kaur B
J Gene Med; 2017 Mar; 19(3):. PubMed ID: 28087981
[TBL] [Abstract][Full Text] [Related]
34. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
[TBL] [Abstract][Full Text] [Related]
35. Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging.
Park I; Bok R; Ozawa T; Phillips JJ; James CD; Vigneron DB; Ronen SM; Nelson SJ
J Magn Reson Imaging; 2011 Jun; 33(6):1284-90. PubMed ID: 21590996
[TBL] [Abstract][Full Text] [Related]
36. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
[TBL] [Abstract][Full Text] [Related]
37. Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.
Lan F; Pan Q; Yu H; Yue X
J Neurochem; 2015 Sep; 134(5):811-8. PubMed ID: 25991372
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo effect of human lactoferrin on glioblastoma growth.
Arcella A; Oliva MA; Staffieri S; Aalberti S; Grillea G; Madonna M; Bartolo M; Pavone L; Giangaspero F; Cantore G; Frati A
J Neurosurg; 2015 Oct; 123(4):1026-35. PubMed ID: 26186026
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
40. p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.
Dinca EB; Lu KV; Sarkaria JN; Pieper RO; Prados MD; Haas-Kogan DA; Vandenberg SR; Berger MS; James CD
Cancer Res; 2008 Dec; 68(24):10034-9. PubMed ID: 19074867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
